Nuvilex to move International Corporate HQ near FDA headquarters

Nuvilex, Inc. (OTCQB: NVLX) announced today it is in the final stages of locating its International Corporate Headquarters near the headquarters of the U.S. Food and Drug Administration (FDA).

By locating the Company's International Corporate offices 4 miles from the U.S. FDA, the Company will have immediate access to the agency's resources. In addition, the new HQ will be located approximately 10 miles from the National Institutes of Health and the National Cancer Institute, both major sources of grants and research collaboration. This move will be of significant value as Nuvilex pursues clinical development of its pancreatic cancer treatment technology as well as additional biotechnology developments planned for the future.

Dr. Robert F. Ryan, Nuvilex's President and CEO commented, "We strongly believe this location will have significant benefits for the Company. Most importantly, it will facilitate our interactions with the FDA, an important part of our overall strategic planning, especially given our recent entry into biotechnology and our plans for expansion in this area."